Cargando…
DNA Replication Licensing Factors: Novel Targets for Cancer Therapy via Inhibiting the Stemness of Cancer Cells
The replication licensing factors strictly regulate the DNA replication origin licensing process to guarantee the stability of the genome. Numerous experimental studies have recently demonstrated that the replication licensing factors as oncogenes are essential for the occurrence and development of...
Autores principales: | Song, Shaoran, Wang, Yaochun, Liu, Peijun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771848/ https://www.ncbi.nlm.nih.gov/pubmed/35173548 http://dx.doi.org/10.7150/ijbs.67529 |
Ejemplares similares
-
Simvastatin suppresses the DNA replication licensing factor MCM7 and inhibits the growth of tamoxifen-resistant breast cancer cells
por: Liang, Zheyong, et al.
Publicado: (2017) -
Simvastatin and Atorvastatin inhibit DNA replication licensing factor MCM7 and effectively suppress RB-deficient tumors growth
por: Li, Juan, et al.
Publicado: (2017) -
Eukaryotic translation initiation factor 3 subunit B could serve as a potential prognostic predictor for breast cancer
por: Song, Shaoran, et al.
Publicado: (2022) -
DNA replication licensing in stem cells: Gatekeeping the commitment to proliferation
por: Coller, Hilary A.
Publicado: (2018) -
DNA Replication Licensing Proteins for Early Detection of Lung Cancer
por: VS, Veena, et al.
Publicado: (2017)